SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
August, 2024
Commission File Number 1-15182
DR. REDDY’S LABORATORIES LIMITED
(Translation of registrant’s name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No x
If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.
EXHIBITS
Exhibit Number |
Description of Exhibits | |
99.1 | Intimation dated August 31, 2024 |
2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
DR. REDDY’S LABORATORIES LIMITED (Registrant) | ||
Date: August 31, 2024 | By: | /s/ K Randhir Singh |
Name: K Randhir Singh | ||
Title: Company Secretary |
3 |
Exhibit 99.1
Dr. Reddy’s Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507
Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Email : mail@drreddys.com www.drreddys.com |
August 31, 2024
National Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ)
BSE Limited (Scrip Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd (Stock Code: DRREDDY)
Dear Sir/Madam,
Sub: | Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 |
This is to inform that the Company has learnt about orders dated August 30, 2024, of National Medical Products Administration, China and National Drug Joint Procurement Office, China, made available through their website. The details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Schedule III Para A Sub Para 20 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are as hereunder:
a | Name of the authority | : | National Medical Products Administration, China (NMPA) and National Drug Joint Procurement Office, China (NDJPO) |
b | Nature and details of the action(s) taken, initiated or order(s) passed | : |
NMPA China recently conducted a remote inspection of the Company’s formulations manufacturing facility (FTO-3) for Atomoxetine Hydrochloride Capsules, and concluded that the production quality management of Atomoxetine Hydrochloride Capsules does not meet the requirements of China’s “Good Manufacturing Practice for Drugs (Revised in 2010)”. The NMPA has suspended the import, sale, and use of the Company’s Atomoxetine Hydrochloride Capsules effective August 30, 2024.
Further, NDJPO, having considered the said order of the NMPA, has decided to cancel Dr. Reddy’s Laboratories Ltd.’s Atomoxetine Hydrochloride Capsules “won” status and list the company on the “Violation List”, suspending the company’s eligibility to participate in national centralized drug procurement activities from August 30, 2024 to February 28, 2026. |
c | Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority | : | Both NMPA and NDJPO orders are dated August 30, 2024 |
d | Details of the violation(s)/ contravention(s) committed or alleged to be committed | : |
As detailed above in para b
|
e | Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible | : | The Company is in the process of ascertaining the monetary impact of the said orders. |
This is for your information and record.
Thanking you.
Yours faithfully,
For Dr. Reddy’s Laboratories Limited
K Randhir Singh
Company Secretary, Compliance Officer and Head-CSR
D4 QXR3P!&'L(.,] ;;Y2> ;C&KWBRV@D-+ZX1FK;=UAUSLB^*YO-A<
MI#BW%,MHV!N,_-4S*:&.ACA-S)HEBIZ5<%SPH( 6+ )H<]0*,#:7**LB[.$[0WG,!IR
M<:0?D" ZZ5%7;6FR5.5I?=-R5),*NMN',DYA$B1XR +@Q/J,M6GPI3#['M[F
MB$(2=8D-P$]&K*,(-"$PL0< ;7Z Y@G&G_?)+&_3_P"6+^8VY'0'3[Z .@.8
M)[*G]J;?GZ %I_K%:J] 6=^2;Y#PZ2-J\2W'UKL91D9[)3?+(%Z59(YEX7
M('F%^>B_U2[A#V'V48*%V^[X@@0-J/1_\[#V;%>56U)OJ&?0&KKJVBJX92+L
MO+F=?;+7=;*ED:$OFJ L;;.YM&H99W
MSG:77V(1F>6]5_T78;?](Q28-$,?HXZ_6SK$T-=O_P Q:;"9S?(;'=:I)]9X
M32P#*/"6!(::SB%5K%'V>6-+XO (/%T!CK)IG-9 TQ6*1UL)$$)KB^R)]5H&
MAH0%"&' CE!Q98=0J!B?WQ2M>'1LK:,2=)'F\Q4<\
MO;"<#&,6,BR!=8Z Y/G/1>"O63W.=M;)(&!-*E^O=[Z$7@BBZQ8:W))(KJ?7
MS5R>IF!4X$E'G(4SP W$-C*F-P
M 6$I&5)H JE2H0P*U7OA966CI#C]@V3$6#9%:MZRL!1@Q8<1EPR(UZT&F)2O
M'@(T18IX#!XLASD(Q$XQG'BS@0%KWB\C/T9QI<>L4$%%@Z/Z1:JM:PQO*\E&
MI<4E&04MR6DAR62,7KU^##A#&' S!&9$+[V<] 4J_>C--+'Y(M-N:SD[FR$3
MY:%522#V^U+_ .5'ENDEGEK/%I[**4. &&B2DPRK C5YR:7D(2%("P9"'S!
M O&^THW&-V5XL6.H9&ZB7SS3J?/=*JPJ EA6G5N[!Q.:IUD?
M2YR$LWRX]GQX%G^-- M"=
QVO C'9?(9RQ\=UJZ[*N5?6;4E)JOLC<3'2*>Z]1I79*U524NDXS364=D([
M!?7\$@+$V$*5HBD2=#YZ%K7FD&C/)+2&Y)Z3;+;NQCCUMPFO&&@G32Y0Q5:+8^424^:8O5IDH=D*E
MQ6I-6)6YV2Q$+4KE>&TMVRZ(U(L)##O(&$SP9Q[BX+Q[ZG*^;T1&+Q*EC'#%T&2-Z22V!9\"+C
MIC2OD4F.4*4AU:&*